Related by context. All words. (Click for frequent words.) 76 median PFS 72 Free Survival PFS 72 Median progression 72 CR nPR 71 % CI #.#-#.# [003] 70 FOLFIRI alone 70 progression TTP 70 plus dexamethasone 70 FOLFOX4 70 achieved CCyR 69 comparator arm 69 Flu Cy 69 plus prednisone 69 lopinavir r arm 69 % CI #.#-#.# [007] 68 FOLFIRI 68 clodronate 68 Partial Response 68 placebo dexamethasone 68 achieved ACR# 68 free survival PFS 68 FOLFOX4 alone 67 SVR# 67 oxycodone CR 67 -#.# log# 67 mitoxantrone plus 67 % Confidence Interval 67 Folfox 67 #mg BID [001] 67 log# copies mL 67 RGT arm 67 8mg/kg 67 lumbar spine BMD 67 Peg IFN 67 PEG IFN 67 plus gemcitabine 67 Operative mortality 67 lopinavir r 67 placebo PBO 67 5-FU/LV 67 pegylated interferon alfa 2b 67 FOLFOX 67 biochemical relapse 66 p = NS 66 Engerix B 66 VELCADE melphalan 66 chlorambucil 66 stage IIIb IV 66 PREZISTA ritonavir 66 ALT elevation 66 XIENCE V PROMUS Stent 66 4mg/kg 66 Newly Diagnosed Multiple Myeloma 66 mcg QD 66 mcg albinterferon alfa 2b 66 XELOX 66 mg TID 66 Median survival 66 HBeAg seroconversion 66 Hazard Ratio 66 mRCC 66 mg qd 66 cEVR 66 plus OBT 65 ug dose 65 HBeAg negative patients 65 Neoadjuvant 65 peginterferon alfa 2a 65 rizatriptan 65 mg QD 65 VcMP 65 low dose cytarabine 65 FOLPI 65 oblimersen 65 YERVOY 65 complete cytogenetic response 65 bortezomib refractory 65 stage IIIB 65 mg m² 65 IFN α 65 TPV r 64 REMICADE monotherapy 64 pT3 64 alfa 2a 64 mcg BID 64 dacarbazine 64 ACTEMRA TM 64 ribavirin RBV 64 adjunctive placebo 64 Kaplan Meier analysis 64 FOLFOX6 64 #mg QD [002] 64 pegylated liposomal doxorubicin 64 CCyR 64 LPV r 64 Doxil ® 64 mitoxantrone 64 CR CRu 64 log# IU mL 64 mg kg dose 64 highly emetogenic 64 Peginterferon Alfa 2a 64 Peginterferon 64 Follicular Lymphoma 64 BARACLUDE ® 64 CIMZIA TM 64 RLAI 64 Hormone Refractory Prostate Cancer 64 COMBIVIR 64 undetectable HBV DNA 64 SPRYCEL ® 64 Partial Responses 64 HBeAg positive patients 64 relapsed MM 64 P = .# 64 resected pancreatic cancer 63 REYATAZ r 63 mcg kg 63 IFN alfa 63 octreotide LAR 63 metastatic malignant 63 Pegylated Interferon 63 irinotecan cisplatin 63 DAS# remission 63 #mg q8h 63 Meets Primary Endpoint 63 certolizumab 63 undetectable HCV RNA 63 mg BID 63 BEACOPP 63 lamivudine monotherapy 63 beta 1a 63 cisplatin vinorelbine 63 severe neutropenia 63 ug kg 63 mg tid 63 tumor progression TTP 63 adefovir treated 63 Alkeran 63 mCi kg 63 mg ustekinumab 63 plus methotrexate 63 metastatic GIST 63 cyclophosphamide methotrexate 63 CIMZIA ™ 63 squamous histology 63 receiving VICTRELIS 63 atazanavir ritonavir 63 dalteparin 63 Pegylated Liposomal Doxorubicin 63 mcg linaclotide 63 TLUS 63 biliary tract cancer 63 Paraplatin ® 63 pooled comparator 63 receiving prophylactic anticoagulation 63 oral diclofenac 63 gemcitabine cisplatin 63 HBeAg + 63 p = #.# [004] 63 Hycamtin ® 63 QTcF 63 underwent surgical resection 63 tipranavir ritonavir 63 Relapsed Refractory 63 pegylated interferon alpha 63 median survivals 63 IU ml 63 Castration Resistant Prostate Cancer 63 mL/min/#.# m 2 63 efavirenz EFV 63 uncoated stent 63 Pemetrexed 63 estramustine 63 q#h 63 piperacillin tazobactam 63 achieved PASI 63 R# #mg BID 63 methotrexate monotherapy 63 Aptivus ® 63 μmol L 63 sirolimus stent 62 Elitek 62 adalimumab Humira 62 Taxotere ® 62 3mg/kg 62 dapagliflozin plus 62 GOUT 62 mg Proellex 62 CPOP R 62 Fludara 62 plus prednisone prednisolone 62 fluorouracil 62 low dose Iluvien 62 infliximab monotherapy 62 CLL SLL 62 endoscopic remission 62 -#.# mg dL [001] 62 mg Lucentis 62 PREZISTA r arm 62 Rate ORR 62 TAXUS p value 62 unresectable stage 62 pT2 62 TMC# r 62 neurologic progression 62 Virologic 62 dacarbazine DTIC 62 naïve HCV 62 baseline FEV 62 evaluable 62 mg/m2 IV 62 Posaconazole 62 biochemical recurrence 62 Acetate Rectal Suppositories 62 Irinotecan 62 mg/m2 dose 62 REYATAZ r arm 62 EDSS scores 62 mutated KRAS 62 recurrent GBM 62 divalproex sodium 62 treatment naļve 62 interferon ribavirin 62 FUSILEV enhances 62 interquartile range 62 MADRS score 62 FluCAM 62 mg q#h 62 abacavir lamivudine 62 treatment naive genotype 62 ULORIC 62 sunitinib Sutent 62 adjunctive ABILIFY 62 Kaplan Meier 62 PegIFN 62 carboplatin paclitaxel 62 rFSH 62 #mg BID [003] 62 decitabine 62 primary patency 62 oral allopurinol 62 ACR# response 62 splenectomized 62 Copegus ribavirin 62 KRAS mutant tumors 62 CI #.#-#.# [001] 61 hours postdose 61 unfractionated heparin UFH 61 ancrod 61 PEG interferon 61 prior nephrectomy 61 5FU 61 Refractory Hodgkin Lymphoma 61 EBMT criteria 61 -#.# mg dL [002] 61 lymphocytosis 61 #Gy 61 EGFR TKI 61 RECIST criteria 61 metastatic malignant melanoma 61 lumbar spine bone 61 ritonavir boosted atazanavir 61 humanized interleukin 6 61 gefitinib Iressa 61 MCyR 61 metastatic renal cell carcinoma 61 Fludarabine 61 nicardipine 61 FluCAM arm 61 Mg Uk 61 Gemcitabine 61 LEXIVA r 61 DAS# CRP 61 oral Hycamtin 61 evaluable subjects 61 ritonavir boosted 61 ximelagatran 61 CHOP chemotherapy 61 dasatinib Sprycel ® 61 cabazitaxel 61 lamivudine refractory patients 61 dose dexamethasone 61 #mg QD [001] 61 adalimumab 61 chemoradiation therapy 61 interferon alfa 61 refractory NSCLC 61 q8h 61 Treatment Naive Patients 61 non splenectomized 61 placebo p = 61 nodular partial response 61 #mg dosing group 61 nadroparin 61 Q2W 61 PASI scores 61 PEG Interferon alfa 61 gemcitabine carboplatin 61 Capecitabine 61 interferon alfa 2a 61 #.#mg/dL 61 #mg/day [001] 61 atorvastatin #mg 61 plus GP IIb 61 leukemia AML 61 cancer mCRC 61 PSADT 61 BUPHENYL R sodium phenylbutyrate 61 amoxicillin clavulanate 61 mg BID dose 61 EOX 61 binary restenosis 61 5 Fluorouracil 61 nonmetastatic 61 microgram kg 61 prednisone prednisolone plus 61 Lenalidomide 61 saline placebo 61 docetaxel pretreated 61 IFL chemotherapy regimen 61 ATV RTV 61 antiretroviral naïve 61 receiving golimumab 61 cyclophosphamide chemotherapy 61 Pred Forte 61 ara C 61 doxazosin 61 Trastuzumab 61 Zometa hazard 61 mitoxantrone chemotherapy 60 biologic DMARD 60 Kaplan Meier estimates 60 RECIST Response Evaluation Criteria 60 Thal Dex 60 mIU ml 60 cisplatin gemcitabine 60 care regimens CCR 60 fatigue asthenia 60 mg/m2/day 60 plus MTX 60 Decitabine 60 Pharmacokinetics PK 60 febrile neutropenia 60 PROSTVAC VF 60 CRp 60 pegylated interferon peg IFN 60 PegIFN RBV 60 Neulasta ® 60 tipranavir r 60 peginterferon alfa 2b 60 KRAS wild 60 achieved sustained virologic 60 partial remissions 60 nonsignificant difference 60 mg p = 60 μg dose 60 pamidronate 60 mg RDEA# 60 evaluable patients 60 cetuximab Erbitux R 60 CIMZIA TM certolizumab pegol 60 goserelin 60 bivalirudin monotherapy 60 HCV RESPOND 2 60 receiving PEGINTRON 60 uM 60 virologic response 60 Viread Emtriva 60 PEGINTRON TM 60 BENICAR HCT 60 Oral Fingolimod 60 TAXUS Stent 60 icatibant 60 Navelbine ® 60 underwent resection 60 Myelodysplastic Syndrome MDS 60 Multiple Myeloma MM 60 BRIM2 60 doripenem 60 doxorubicin cyclophosphamide 60 locoregional 60 azacitidine 60 achieved statistical significance 60 oral clodronate 60 AZT zidovudine Retrovir 60 ZACTIMA 60 titrated glipizide plus 60 Stage IIIb 60 generalized edema 60 alfa 2b 60 FDA defined valvulopathy 60 detectable HCV RNA 60 tolterodine ER 60 preoperative chemotherapy 60 % CI #.#-#.# [008] 60 CD3 + 60 tapentadol ER 60 receiving ISENTRESS 60 Monotherapy 60 EGFR mutation positive 60 complete cytogenetic 60 plus aztreonam 60 Cream USP 1 60 #mg/kg [002] 60 mCi m 2 60 mCRPC 60 Epoetin Alfa 60 HBeAg negative 60 HCV SPRINT 60 PROCTOCORT ® Suppository Hydrocortisone 60 Primary Endpoint 60 daunorubicin 60 patients evaluable 60 rimonabant #mg 60 log# 60 NMIBC 60 experienced virologic failure 60 locoregional control 60 -#.# log# copies mL 60 cytogenetic response 60 vincristine doxorubicin 60 ORENCIA ® 60 p = #.# [002] 60 mycophenolate mofetil 60 azathioprine 60 HBeAg 60 Target Lesion Revascularization TLR 60 posttreatment 60 NEVO 60 Left Ventricular Ejection Fraction 60 ADAS cog 60 EURIDIS 60 sunitinib malate 60 daily Infergen 59 relapsed refractory multiple myeloma 59 sunitinib Sutent ® 59 plus ribavirin 59 Crohn Disease Activity 59 stage IIIb 59 mg hydrochlorothiazide 59 pg mL 59 ABC/3TC 59 remission CR 59 #mg BID [002] 59 leukopenia 59 mcg dose 59 cells uL 59 docetaxel chemotherapy 59 salmeterol fluticasone propionate 59 PSA nadir 59 adriamycin 59 sustained virologic response 59 melphalan prednisone 59 #ug [001] 59 salmeterol fluticasone 59 DOXIL 59 ARCOXIA 59 nondiabetic patients 59 Cutaneous T 59 relapsed CLL 59 Psoriasis Area 59 #mg/day [002] 59 Nilotinib 59 metastatic castration resistant 59 Response Evaluation Criteria 59 invasive carcinomas 59 Navelbine 59 Metastatic Colorectal Cancer 59 noninferior 59 ‰ ¥ 59 Hazard Ratio HR 59 interferon gamma 1b 59 morphometric vertebral fractures 59 #.#/#.# mmHg [001] 59 paclitaxel carboplatin 59 NATRECOR R 59 ACR# responses 59 Temsirolimus 59 HIV RNA 59 CsA 59 GLIADEL R Wafer 59 Peginterferon alfa 2b 59 Amrubicin 59 glufosfamide 59 Viread Emtriva Sustiva 59 KRAS mutations occur 59 CRu 59 baseline HbA1c 59 TAXOTERE R 59 recurrent NSCLC 59 HBeAg positive 59 Solid Tumors RECIST 59 Mg Usa 59 microbiological eradication 59 Unfractionated Heparin 59 CYP#A# substrate 59 Solid Tumors criteria 59 preintervention 59 Sustained virologic response 59 vandetanib 59 infusional 5-FU/LV 59 postoperative chemotherapy 59 anthracycline taxane 59 hypophosphatemia 59 treatment naïve genotype 59 postintervention 59 APTIVUS r 59 BMS p = 59 del 5q 59 CANCIDAS 59 Rapid Virologic Response 59 PANSS scores 59 candesartan cilexetil 59 recurrent GBM patients 59 mCRC patients 59 oxycodone IR 59 receiving INTRON 59 desvenlafaxine succinate 59 alpha 2a 59 metastatic CRC 59 plus COPEGUS 59 log# reduction 59 response CCyR 59 Consensus +#.# 59 mg/# hours 59 DAPT 59 neuropathy sensory 59 leuprorelin 59 sorafenib Nexavar 59 pegaptanib 59 budesonide pMDI 59 imiquimod cream 59 TIMP 1 59 refractory AML 59 p = .# [002] 59 mg subcutaneous 59 oral rivaroxaban 59 evaluating tivozanib 59 Gemzar ® 59 colorectal metastases 59 HCV Genotype 59 peg interferon 59 CAELYX 59 docetaxel prednisone 59 completely resected 59 tenecteplase 59 Gastrointestinal Stromal Tumors 59 locoregional disease 59 mg clopidogrel 59 p = ns 59 chronic HCV genotype 59 subcutaneously administered 59 Relapsed 59 HCV genotype 59 doxorubicin docetaxel 59 confidence interval #.#-#.# 59 lispro 59 flutamide 59 VFEND 59 adefovir 59 anagrelide 59 sustained virological response 59 Index CDAI 59 #mg dose [002] 59 colesevelam HCl 59 PEGylated Fab fragment 59 metastatic RCC 59 CDAI 59 Contrave# 59 microg 58 mitomycin 58 TAXUS Express Stent 58 recurrent glioblastoma multiforme 58 sipuleucel T 58 gp# vaccine 58 n = 58 NRTI sparing 58 median CD4 58 aminotransferase elevations greater 58 pegylated interferon alfa 58 adjuvant cisplatin 58 Viread Emtriva SUSTIVA 58 Nebulized 58 ® fluocinonide Cream 58 tobramycin inhalation solution 58 mean baseline A1C 58 CYPHER Stent 58 ISEL 58 sirolimus eluting stent 58 locoregional recurrence 58 baseline LDH 58 IRLS score 58 Subgroup analysis 58 concurrent chemoradiation 58 sd = 58 receiving highly emetogenic 58 mg/# h 58 deep venous thromboses 58 Jevtana 58 dacarbazine chemotherapy 58 Idiopathic Pulmonary Fibrosis 58 Ishak fibrosis score 58 ErbB2 positive 58 #mg/m# [001] 58 antiretroviral naive 58 ischemia driven 58 Patency 58 statistically significant p = 58 rectal tenesmus 58 TURBT 58 anemia hemoglobin 58 virologic failure 58 mg q8h 58 Tarceva TM 58 TAXUS Liberte Long 58 refractory chronic lymphocytic 58 iniparib BSI 58 amprenavir 58 Halaven 58 pmol L 58 azilsartan medoxomil 58 annualized relapse 58 Natalizumab 58 mL/min/#.# m2 58 Papillary 58 univariate analysis 58 stage IIIB IV 58 PEGylated anti 58 dasatinib Sprycel 58 hip BMD 58 standard chemotherapy regimen 58 STELARA 58 mg administered orally 58 mm Stent 58 cyclophosphamide doxorubicin vincristine 58 TRANSFORMS 58 placebo Hazard Ratio 58 ER CHOP 58 rapid virologic response 58 Topotecan 58 mg Androxal 58 relapsing multiple sclerosis 58 COPEGUS 58 somatostatin analog 58 active comparator 58 ACR# ACR# 58 diameter stenosis 58 #R #R #R [002] 58 mcg Albuferon 58 venlafaxine XR 58 TYKERB 58 HbA1c levels 58 peginterferon alfa 58 CI #.#-#.# [002] 58 satraplatin Phase 58 ertapenem 58 follicular lymphomas 58 IRESSA 58 carboplatin chemotherapy 58 mapatumumab 58 lymphoid malignancies 58 Sprycel dasatinib 58 DAS# [002] 58 AEGR 58 tenofovir emtricitabine 58 NEVO ™ 58 Hazard Ratio = 58 ABVD 58 Lantus ® 58 EDSS score 58 fluorouracil leucovorin 58 galiximab 58 peginterferon 58 telaprevir dosed 58 REYATAZ ® 58 % CI #.#-#.# [006] 58 voriconazole 58 epirubicin cyclophosphamide 58 CALGB # [002] 58 baminercept 58 bendamustine 58 pegylated interferon alfa 2a 58 advanced hepatocellular carcinoma 58 BRIM3 58 mmol kg 58 sUA 58 CIBIC plus 58 hypokalemia 58 anaplastic astrocytomas 58 Randomized Evaluation 58 malignancy HCM 58 ALVESCO 58 Stage IIB 58 Pain Intensity 58 seroconverted 58 achieved sustained virological 58 ibandronate 58 moderate renal impairment 58 TAXUS ATLAS 58 prospectively defined 58 MAGE A3 ASCI 58 confirmed CCyR 58 fluoropyrimidine 58 idraparinux 58 dosing cohorts 58 #.#g/day 58 VIRAMUNE 58 oral hypoglycemic agent 58 Retreatment 58 BR.# 58 systemic anaplastic large 58 μg doses 58 basiliximab 58 mmol l 58 HAQ DI 58 ARIXTRA 58 CI #.#-#.# p = 58 achieved mucosal healing 58 posaconazole 58 titrated glipizide 58 iodixanol 58 splenectomized patients 58 ezetimibe simvastatin 58 oral antidiabetic medication 58 MabCampath 58 pCR 58 thalidomide Thalomid 58 cGy 58 randomized multicenter trial 58 Raptiva r 58 μg kg 58 minimally symptomatic metastatic castrate 57 Malignant Melanoma 57 angiographic outcomes 57 evaluating Xcytrin 57 fosamprenavir 57 0 KICKOFF RETURNS 57 receiving SIMPONI 57 prior relapsers 57 teriflunomide 57 resistant hormone refractory 57 pimecrolimus cream 57 MACCE 57 ribavirin therapy 57 Erlotinib 57 dexmedetomidine 57 6 mercaptopurine 57 AVONEX ® 57 HLA DR2 57 pegylated interferon alpha 2a 57 Kaplan Meier method 57 FASLODEX 57 assessing T DM1 57 imatinib Gleevec ® 57 OS = ISD/#/#/# 57 receptor tyrosine kinase inhibitor 57 pancreatic adenocarcinoma 57 #μg [002] 57 pemetrexed 57 LVEF 57 stomatitis pharyngitis 57 localized renal 57 RNA copies mL 57 Sustained Virologic Response 57 leukocyte count 57 AUC0 57 FROVA 57 tirofiban 57 abiraterone acetate 57 Renal Cell Carcinoma RCC 57 ceftazidime 57 mITT population 57 clinically evaluable patients 57 HOMA IR 57 SUVmax 57 patients receiving ERBITUX 57 Aflibercept 57 IV NSCLC 57 insulin detemir 57 vinorelbine 57 IIIa inhibitor 57 CI -#.# 57 dose cohort 57 Rating Scale MADRS 57 administered subcutaneously 57 glipizide plus 57 bosentan 57 eribulin 57 null responder HCV 57 GnRH agonist 57 EDEMA3 57 Platelet counts 57 mg/# hr 57 ziprasidone 57 Diffuse Large B 57 Scale cognitive subscale 57 interquartile range IQR 57 recurrent VTE 57 cinacalcet 57 metoprolol tartrate 57 dexamethasone Decadron 57 COZAAR 57 drotrecogin alfa activated 57 Platinol ® cisplatin 57 mU liter 57 Scale EDSS 57 pmol liter 57 gemcitabine Gemzar 57 Squamous 57 peginterferon alfa 2a #KD 57 #mg/m# [002] 57 Capesaris 57 PREZISTA r 57 insulin glulisine 57 definite stent thrombosis 57 urate lowering therapy 57 pg ml 57 nilotinib 57 tocilizumab 57 Annualized ROE 57 HbA 1c levels 57 seropositive patients 57 Bortezomib 57 chemoradiotherapy 57 #mg #mg #mg [003] 57 Score TOS 57 cytarabine daunorubicin 57 plus medroxyprogesterone acetate 57 Velcade bortezomib 57 % CI #.#-#.# [005] 57 ALND 57 Stent p = 57 q# 57 p ≤ 57 dose cytarabine 57 p = .# [001] 57 subcutaneous enoxaparin 57 genotypic resistance 57 LANTUS R 57 Cimzia TM 57 virological response 57 Adalimumab 57 trabedersen 57 Torisel 57 femoral neck BMD 57 #mg doses [002] 57 Glioblastoma Multiforme 57 Malignant Glioma 57 relapsed multiple myeloma 57 Myelofibrosis 57 Hb A1C 57 NPH insulin 57 Paraplatin 57 castrate resistant 57 interferon alfa 2b 57 K ras mutations 57 refractory CTCL 57 invasive aspergillosis 57 PEGASYS ® 57 ADAS Cog 57 mIU mL 57 â ‰ ¥ 57 cyclophosphamide FC 57 mg kg belimumab 57 prostate cancer HRPC 57 HAM D# scores 57 plasma HCV RNA 57 metastatic neuroendocrine tumors 57 tamsulosin 57 recurrent metastatic 57 undetectable virus HCV 57 radiotherapy RT 57 androgen suppression 57 & s2 = 57 XIENCE V vs. 57 RAPTIVA 57 lymphopenia 57 GG genotype 57 MGd 57 sargramostim 57 brivaracetam 57 comparator PI r 57 plasma uric acid 57 anastrazole 57 unresectable 57 hepatorenal syndrome 57 Hypomagnesemia occurred 57 MACUGEN 57 MELD scores 57 solifenacin 57 erlotinib Tarceva 57 ZOLINZA 57 acute bipolar mania 57 Dacogen injection 57 mg subcutaneously 57 mg + GLY 57 CLARITY study 57 debulking surgery 57 ADVEXIN efficacy 57 Taxus Stent 57 mild renal insufficiency 57 irbesartan 57 Tiotropium 57 Durezol 57 nadolol 57 CK # plasma concentrations 57 fludarabine cyclophosphamide 57 temsirolimus 57 Bezielle 57 BCIRG 57 cells μL 57 Kaplan Meier estimate 57 placebo fluoxetine 57 postmenopausal osteoporotic women 57 disease progression TTP 57 BENICAR 57 NNT = 57 serum phosphorus 57 epoetin alfa 57 quetiapine 57 Pegasys ® 57 tumor xenograft models 57 demonstrated antitumor activity 57 mcg doses 57 prior chemotherapy regimens 57 advanced adenoma 57 ® lenalidomide 57 confidence interval CI 57 levosimendan 57 telaprevir pegylated interferon 57 palifermin 57 gefitinib 56 Abciximab 56 ug mL 56 bladder carcinoma 56 Its ROA 56 events MACE 56 infusional 56 Myelodysplastic Syndromes 56 moderately emetogenic 56 HPV-#/# 56 oral vancomycin 56 advanced pancreatic neuroendocrine 56 multicenter randomized controlled 56 gastrointestinal stromal tumor GIST 56 colorectal carcinomas 56 R rilonacept Injection 56 reduce serum phosphate 56 1mg 2mg 56 CDAI score 56 TORISEL 56 Epratuzumab 56 NOXAFIL 56 LV dysfunction 56 Stent thrombosis 56 Alocrest 56 erlotinib Tarceva ® 56 ECOG PS 56 mucosal healing 56 blastic phase 56 Hamilton Anxiety Scale 56 corticosteroid dose 56 ISTODAX ® 56 plus glycoprotein IIb 56 mg d 56 dose escalation phase 56 abnormal p# biomarker 56 ATACAND 56 thrombocytopenic 56 pegIFN 56 de novo AML 56 REYATAZ R 56 ACZ# 56 QD dosing 56 echocardiographic parameters 56 R entecavir 56 cilostazol 56 R abatacept 56 ARCALYST ® 56 mm3 56 unstable angina pectoris 56 darunavir r 56 Severity Index PASI 56 adjuvant colon cancer 56 FLT3 ITD 56 prucalopride 56 liver histology 56 postop 56 Systemic Sclerosis 56 low dose dexamethasone 56 tacrolimus ointment 56 Teriflunomide 56 virologically suppressed 56 APTIVUS R 56 Timed Walk 56 haematologic 56 fulvestrant 56 preoperative PSA